REGULATORY

Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash

January 21, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Novartis Pharma’s asthma drug Xolair (omalizumab) will become the first drug to face a new special re-pricing rule to be introduced in April after its label expansion to pollen allergy last December, while MSD’s I/O star Keytruda (pembrolizumab) will get…

To read the full story

Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020

REGULATORY

LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026
Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…